Padrão ((~JJ)_JJ_NN_IN)_(NN_(~NN)) - onde (~JJ) é para não chocar com a regra 1.2

#Sem nome próprio
1. Java: (?:(?:(?:[\\w-/]*_(?:[^J]..?|J[^J].?)\\s)[\\w-/]*_JJ[RS]?\\s)[\\w-/]*_NN[S]?\\s[\\w-/]*_IN)(\\s[\\w-/]*_NN[S]?)(?:\\s[\\w-/]*_(?:[^N]..?|N[^N].?)|\\s\\._|\\s,_|\\s:_|\\s;_|$)
2. Perl: (?:(?:(?:[\w-/]*_(?:[^J]..?|J[^J].?)\s)[\w-/]*_JJ[RS]?\s)[\w-/]*_NN[S]?\s[\w-/]*_IN)(\s[\w-/]*_NN[S]?)(?:\s[\w-/]*_(?:[^N]..?|N[^N].?)|\s\._|\s,_|\s:_|\s;_|$)
	// \w Casa letras, dígitos, ou '_'.
	// 1 e 2 são equivalentes
	// Regra termina com ponto final, vírgula, ponto e vírgula, dois pontos ou $.
	// Teve termo com nome próprio (NNP), falso positivo

Sentences Examples:

She_PRP died_VBD during_IN the_DT second_JJ year_NN of_IN therapy_NN from_IN acute_JJ severe_JJ anemia_NN during_IN an_DT episode_NN of_IN splenic_JJ sequestration_NN ._.     						

Recurrent_JJ stroke_NN occurred_VBD in_IN one_CD patient_NN after_IN 6_CD years_NNS of_IN follow-up_JJ despite_IN evidence_NN of_IN good_JJ compliance_NN with_IN therapy_NN as_IN assessed_VBN by_IN hematologic_JJ response_NN to_TO HU_NNP ._. 					

Toxicities_NNS of_IN HU_NNP were_VBD reported_VBN with_IN 2_CD transient_JJ episodes_NNS of_IN thrombocytopenia_NN -LRB-_-LRB- 2_CD infants_NNS -RRB-_-RRB- that_WDT required_VBD temporary_JJ discontinuation_NN of_IN therapy_NN ._. 

This_DT observation_NN suggests_VBZ that_IN the_DT increase_NN in_IN MCV_NNP may_MD have_VB a_DT direct_JJ effect_NN on_IN the_DT adhesive_JJ phenotype_NN of_IN sickle_NN cells_NNS and_CC that_IN monitoring_VBG the_DT increase_NN of_IN MCV_NNP may_MD be_VB used_VBN as_IN indirect_JJ evidence_NN of_IN the_DT decrease_NN of_IN the_DT adhesive_JJ phenotype_NN of_IN erythrocytes_NNS in_IN patients_NNS with_IN sickle_JJ cell_NN anemia_NN treated_VBN with_IN hydroxyurea_NN ._. 

Discontinuation_NN of_IN transfusion_NN after_IN at_IN least_JJS 30_CD months_NNS in_IN patients_NNS who_WP have_VBP converted_VBN to_TO normal_JJ velocities_NNS was_VBD associated_VBN with_IN high_JJ risk_NN of_IN reversion_NN to_TO abnormal_JJ and_CC chance_NN of_IN stroke_NN ._. 

Those_DT with_IN persistently_RB abnormal_JJ TCD_NNP results_NNS despite_IN transfusion_NN often_RB have_VBP severe_JJ vasculopathy_NN and_CC are_VBP at_IN much_RB higher_JJR risk_NN for_IN stroke_NN ._.

One_CD occurred_VBD after_IN 3_CD months_NNS of_IN treatment_NN in_IN a_DT child_NN in_IN whom_WP stroke_NN was_VBD the_DT only_JJ indication_NN for_IN hydroxyurea_NN ._. 

The_DT second_JJ one_CD occurred_VBD in_IN a_DT child_NN whose_WP$ past_JJ history_NN of_IN stroke_NN was_VBD not_RB the_DT reason_NN advocated_VBN by_IN his_PRP$ physician_NN for_IN hydroxyurea_NN treatment_NN ,_, this_DT reason_NN being_VBG the_DT existence_NN of_IN painful_JJ crises_NNS ._. 

Patients_NNS who_WP were_VBD 20_CD or_CC more_JJR years_NNS of_IN age_NN had_VBD a_DT more_RBR severe_JJ course_NN than_IN those_DT who_WP were_VBD younger_JJR ._. 

Eighteen_CD patients_NNS died_VBD ,_, and_CC the_DT most_RBS common_JJ causes_NNS of_IN death_NN were_VBD pulmonary_JJ emboli_NNS and_CC infectious_JJ bronchopneumonia_NN ._. 

The_DT primary_JJ causes_NNS of_IN death_NN were_VBD  respiratory_JJ failure_NN from_IN pulmonary_JJ emboli_NNS -LRB-_-LRB- bone_NN marrow_NN ,_, fat_NN ,_, or_CC thrombotic_JJ -RRB-_-RRB- in_IN six_CD patients_NNS and_CC bronchopneumonia_NN in_IN six_CD ._.
					
Nomes próprios:
	the_DT first_JJ year_NN of_IN HU_NNP ._. 
	an_DT early_JJ start_NN of_IN HU_NNP in_IN 
	a_DT classical_JJ complication_NN of_IN SCD_NNP 
	
Conclusão: traz muito lixo!!!


Bate nas duas regras:					   	  
		evidence_NN of_IN good_JJ compliance_NN with_IN   					((JJ)_NN)_IN_(JJ_NN_(~NN))  4º padrão
					of_IN good_JJ compliance_NN with_IN therapy_NN as_IN    (~JJ)JJ_NN_IN_NN(~NN)		6º padrão		
 